Rotigotine
- Generic Name
- Rotigotine
- Brand Names
- Neupro
- Drug Type
- Small Molecule
- Chemical Formula
- C19H25NOS
- CAS Number
- 99755-59-6
- Unique Ingredient Identifier
- 87T4T8BO2E
- Background
Rotigotine (Neupro) is a non-ergoline dopamine agonist indicated for the treatment of Parkinson's disease (PD) and restless legs syndrome (RLS) in Europe and the United States. It is formulated as a once-daily transdermal patch which provides a slow and constant supply of the drug over the course of 24 hours.
...
- Indication
For use/treatment in neurologic disorders and parkinson's disease as well as moderate-to-severe primary Restless Legs Syndrome.
- Associated Conditions
- Moderate restless legs syndrome (RLS), Parkinson's Disease (PD), Severe restless legs syndrome (RLS)
- Associated Therapies
- -
A Trial to Evaluate the Effects of Rotigotine Transdermal Patch on Early Morning Motor Impairment and Sleep Disorders Idiopathic Parkinson's Disease
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-10-25
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 58
- Registration Number
- NCT00243945
- Locations
- 🇩🇪
Schwarz, Monheim, Germany
A Trial To Assess Switching From Ropinirole, Pramipexole Or Cabergoline To The Rotigotine Transdermal System In Idiopathic Parkinson's Disease
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-10-19
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- UCB Pharma
- Registration Number
- NCT00242008
- Locations
- 🇺🇸
Schwarz, RTP, North Carolina, United States
Three Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Leg Syndrome
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-08-26
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 549
- Registration Number
- NCT00136045
- Locations
- 🇩🇪
Schwarz, Monheim, Germany
Four Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Legs Syndrome
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-08-26
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 811
- Registration Number
- NCT00135993
- Locations
- 🇺🇸
Schwarz, RTP, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath